Provectus Biopharmaceuticals (PVCT) 10-Q 9 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 09, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-36457
Entity Registrant Name	PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000315545
Entity Tax Identification Number	90-0031917
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	800 S Gay Street
Entity Address, Address Line Two	Suite 1610
Entity Address, City or Town	Knoxville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37929
City Area Code	866
Local Phone Number	594-5999
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		419,547,119

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 67,030	$ 682,984
Restricted cash	1,644,321	2,423,958
Short-term receivables	564	5,107
Prepaid expenses and other current assets	187,500	329,908
Total Current Assets	1,899,415	3,441,957
Equipment and furnishings, less accumulated depreciation of $100,035 and $91,178, respectively	22,979	31,836
Operating lease right-of-use asset	128,059	39,563
Total Assets	2,050,453	3,513,356
Current Liabilities:
Accounts payable	1,941,315	1,287,459
Deposit for purchase of Series D-1 Preferred Stock		150,000
Unearned grant revenue	1,675,795	2,500,000
Other accrued expenses	2,444,224	2,002,486
Accrued interest	104,589	10,578
Accrued interest - related parties	22,569	6,044
Notes payable	72,135	238,452
Convertible notes payable	1,810,000	1,260,000
Convertible notes payable - related parties	710,000	200,000
Operating lease liability, current portion	43,377	45,617
Total Current Liabilities	8,824,004	7,700,636
Operating lease liability, non-current portion	85,019
Total Liabilities	8,909,023	7,700,636
Commitments, contingencies, and litigations (Note 12)
Stockholders’ Deficit:
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 419,497,119 shares issued and outstanding at September 30, 2022 and 419,447,119 issued and outstanding at December 31, 2021	419,497	419,447
Additional paid-in capital	241,593,029	241,440,106
Accumulated other comprehensive loss	(36,752)	(34,467)
Accumulated deficit	(248,855,988)	(246,033,958)
Total Stockholders’ Deficit	(6,858,570)	(4,187,280)
Total Liabilities and Stockholders’ Deficit	2,050,453	3,513,356
Series D Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value	12,373	12,373
Series D-1 Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value	$ 9,271	$ 9,219

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Accumulated depreciation, equipment and furnishings	$ 100,035	$ 91,178
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	419,497,119	419,447,119
Common stock, shares outstanding	419,497,119	419,447,119
Series D Convertible Preferred Stock [Member]
Preferred stock, shares authorized	12,374,000	12,374,000
Preferred stock, shares issued	12,373,247	12,373,247
Preferred stock, shares outstanding	12,373,247	12,373,247
Preferred stock, liquidation preference value	$ 14,164,889	$ 14,164,889
Series D-1 Convertible Preferred Stock [Member]
Preferred stock, shares authorized	11,241,000	11,241,000
Preferred stock, shares issued	9,270,860	9,218,449
Preferred stock, shares outstanding	9,270,860	9,218,449
Preferred stock, liquidation preference value	$ 106,132,320	$ 105,532,804

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Grant Revenue	$ 314,890		$ 824,205
Operating Expenses:
Research and development	580,390	608,653	2,068,154	1,866,776
General and administrative	400,689	438,578	1,500,278	1,583,148
Total Operating Expenses	981,079	1,047,231	3,568,432	3,449,924
Total Operating Loss	(666,189)	(1,047,231)	(2,744,227)	(3,449,924)
Other Income/(Expense):
Research and development tax (deficit)/credit	(638)	(507)	37,621	31,637
Gain from extinguishment				63,094
Interest expense, net	(46,440)	(3,521)	(115,424)	(945,607)
Total Other Expense, Net	(47,078)	(4,028)	(77,803)	(850,876)
Net Loss	$ (713,267)	$ (1,051,259)	$ (2,822,030)	$ (4,300,800)
Basic and Diluted Loss Per Common Share	$ 0	$ 0	$ (0.01)	$ (0.01)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	419,489,239	409,961,614	419,461,313	405,286,784

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Net Loss	$ (713,267)	$ (1,051,259)	$ (2,822,030)	$ (4,300,800)
Other Comprehensive Loss:
Foreign currency translation adjustments	(1,241)	(193)	(2,285)	(477)
Total Comprehensive Loss	$ (714,508)	$ (1,051,452)	$ (2,824,315)	$ (4,301,277)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series D Convertible Preferred Stock [Member]	Preferred Stock [Member] Series D-1 Convertible Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member] Series D Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Series D-1 Convertible Preferred Stock [Member]	Total
Beginning, balance, value at Dec. 31, 2020					$ 398,808	$ 209,923,347	$ (34,097)	$ (240,494,415)		$ (30,206,357)
Beginning balance, shares at Dec. 31, 2020			100		398,807,037
Common stock issued upon exercise of warrants					$ 4,500	235,350				239,850
Common stock issued upon exercise of warrants, shares					4,500,000
Common stock					$ 250	19,500				19,750
Common stock, shares					250,000
Net loss								(1,669,950)		(1,669,950)
Other comprehensive loss							837			837
Balance, value at Mar. 31, 2021					$ 403,558	210,178,197	(33,260)	(242,164,365)		(31,615,870)
Ending balance, shares at Mar. 31, 2021			100		403,557,037
Beginning, balance, value at Dec. 31, 2020					$ 398,808	209,923,347	(34,097)	(240,494,415)		(30,206,357)
Beginning balance, shares at Dec. 31, 2020			100		398,807,037
Net loss										(4,300,800)
Balance, value at Sep. 30, 2021		$ 9,219		12,373	$ 419,448	241,440,106	(34,574)	(244,795,215)		(2,948,643)
Ending balance, shares at Sep. 30, 2021	12,373,247	9,218,449			419,447,119
Beginning, balance, value at Mar. 31, 2021					$ 403,558	210,178,197	(33,260)	(242,164,365)		(31,615,870)
Beginning balance, shares at Mar. 31, 2021			100		403,557,037
Common stock issued upon exercise of warrants					$ 200	10,460				10,660
Common stock issued upon exercise of warrants, shares					200,000
Common stock					$ 25	1,650				1,675
Common stock, shares					25,000
Warrants						488				488
Conversion of PRH Notes to Series D Preferred Stock				12,373		3,528,849				3,541,222
Conversion of PRH Notes to Series D Preferred Stock, shares	12,373,247
Conversion of PRH Notes to Series D-1 Preferred Stock		$ 9,441				27,022,417				27,031,858
Conversion of PRH Notes to Series D-1 Preferred Stock, shares		9,440,594
Net loss								(1,579,591)		(1,579,591)
Other comprehensive loss							(1,121)			(1,121)
Balance, value at Jun. 30, 2021		$ 9,441		12,373	$ 403,783	240,742,061	(34,381)	(243,743,956)		(2,610,679)
Ending balance, shares at Jun. 30, 2021	12,373,247	9,440,594	100		403,782,037
Common stock issued for services
Common stock issued upon exercise of warrants					$ 13,353	698,360				711,713
Common stock issued upon exercise of warrants, shares					13,352,966
Common stock					$ 25	1,750				1,775
Common stock, shares					25,000
Conversion of Series B Preferred Stock to Common Stock					$ 66	(66)
Conversion of Series B Preferred Stock to Common Stock, shares			(100)		65,666
Conversion of Series D-1 Preferred Stock to Common Stock		$ (222)			$ 2,221	(1,999)
Conversion of Series D-1 Preferred Stock to Common Stock, shares		(222,145)			2,221,450
Net loss								(1,051,259)		(1,051,259)
Other comprehensive loss							(193)			(193)
Balance, value at Sep. 30, 2021		$ 9,219		$ 12,373	$ 419,448	241,440,106	(34,574)	(244,795,215)		(2,948,643)
Ending balance, shares at Sep. 30, 2021	12,373,247	9,218,449			419,447,119
Beginning, balance, value at Dec. 31, 2021	$ 12,373	$ 9,219			$ 419,447	241,440,106	(34,467)	(246,033,958)		(4,187,280)
Beginning balance, shares at Dec. 31, 2021	12,373,247	9,218,449			419,447,119
Series D-1 Preferred Stock issued for cash		$ 52				149,948				150,000
Series D-1 Preferred Stock issued for cash, shares		52,411
Net loss								(1,030,922)		(1,030,922)
Other comprehensive loss							(716)			(716)
Balance, value at Mar. 31, 2022	$ 12,373	$ 9,271			$ 419,447	241,590,054	(35,183)	(247,064,880)		(5,068,918)
Ending balance, shares at Mar. 31, 2022	12,373,247	9,270,860			419,447,119
Beginning, balance, value at Dec. 31, 2021	$ 12,373	$ 9,219			$ 419,447	241,440,106	(34,467)	(246,033,958)		(4,187,280)
Beginning balance, shares at Dec. 31, 2021	12,373,247	9,218,449			419,447,119
Series D-1 Preferred Stock issued for cash									$ 150,000
Series D-1 Preferred Stock issued for cash, shares									52,411
Net loss										(2,822,030)
Balance, value at Sep. 30, 2022	$ 12,373	$ 9,271			$ 419,497	241,593,029	(36,752)	(248,855,988)		(6,858,570)
Ending balance, shares at Sep. 30, 2022	12,373,247	9,270,860			419,497,119
Beginning, balance, value at Mar. 31, 2022	$ 12,373	$ 9,271			$ 419,447	241,590,054	(35,183)	(247,064,880)		(5,068,918)
Beginning balance, shares at Mar. 31, 2022	12,373,247	9,270,860			419,447,119
Net loss								(1,077,841)		(1,077,841)
Other comprehensive loss							(328)			(328)
Balance, value at Jun. 30, 2022	$ 12,373	$ 9,271			$ 419,447	241,590,054	(35,511)	(248,142,721)		(6,147,087)
Ending balance, shares at Jun. 30, 2022	12,373,247	9,270,860			419,447,119
Common stock					$ 50	2,975				3,025
Common stock, shares					50,000
Net loss								(713,267)		(713,267)
Other comprehensive loss							(1,241)			(1,241)
Balance, value at Sep. 30, 2022	$ 12,373	$ 9,271			$ 419,497	$ 241,593,029	$ (36,752)	$ (248,855,988)		$ (6,858,570)
Ending balance, shares at Sep. 30, 2022	12,373,247	9,270,860			419,497,119

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows From Operating Activities:
Net loss	$ (2,822,030)	$ (4,300,800)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	3,025	23,688
Non-cash lease expense	41,947	62,085
Depreciation	8,857	9,648
Gain on forgiveness of PPP Loan and interest		(63,094)
Changes in operating assets and liabilities
Short term receivables	4,351	2,448
Prepaid expenses and other current assets	142,129	145,639
Accounts payable	654,017	302,978
Unearned grant revenue	(824,205)
Other accrued expenses	442,355	306,116
Operating lease liability	(47,664)	(66,246)
Accrued interest	110,536	942,257
Net Cash Used In Operating Activities	(2,286,682)	(2,635,281)
Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable	550,000	1,700,000
Proceeds from issuance of convertible notes payable - related parties	510,000	200,000
Repayment of short-term note payable	(166,317)	(219,172)
Deposit for purchase of Series D-1 Preferred Stock		150,000
Proceeds from exercise of warrants		962,223
Net Cash Provided By Financing Activities	893,683	2,793,051
Effect of exchange rates on cash, cash equivalents, and restricted cash	(2,592)	(918)
Net (Decrease) Increase In Cash, Cash Equivalents, and Restricted Cash	(1,395,591)	156,852
Cash, Cash Equivalents, and Restricted Cash, Beginning of Period	3,106,942	97,231
Cash, Cash Equivalents, and Restricted Cash, End of Period	1,711,351	254,083
Cash and cash equivalents	67,030	254,083
Restricted cash	1,644,321
Supplemental Disclosures of Cash Flow Information:
Interest
Income taxes
Non-cash investing and financing activities:
Purchase of insurance policies financed by short-term note payable	(57,146)	(282,667)
Deposit applied to equity issuances	(150,000)
Conversion of non-amended 2017 Notes to Series D Preferred Stock		3,541,222
Conversion of amended 2017 Notes and 2020 Notes to Series D-1 Preferred Stock		27,031,858
Conversion of Series D-1 Preferred Stock to Common stock		222
Right-of-use asset for lease liability	$ 130,422

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	1. Business Organization, Nature of Operations and Basis of Presentation Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or “the Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-modulators called halogenated xanthenes (“HXs”). Our lead molecule is named rose bengal sodium (“RBS”). The Company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of our current clinical development programs and the preclinical formulations of our current drug discovery programs. Importantly, our pharmaceutical-grade RBS displays different therapeutic effects at different concentrations and can be formulated for delivery by different routes of administration, The Company believes that RBS targets disease in a bifunctional manner. First, direct contact may lead to cell death or repair depending on the disease being treated and the concentration of the RBS utilized in the treatment. Secondly, multivariate immune signaling, activation, and response may follow that may manifest as stimulatory, inhibitory, or both. The Company believes that it is the first entity to advance an RBS formulation into clinical trials for the treatment of a disease, such as those trials reported on the clinical trials registry ClinicalTrials.gov. The Company believes that it is the first and only entity to date to successfully, reproducibly, and consistently make pharmaceutical-grade RBS at a purity of nearly 100%. The Company’s small molecule HX medical science platform comprises a number of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo in vitro Risks and Uncertainties The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates. Severe acute respiratory syndrome (“SARS”) coronavirus (“CoV”) 2 (“SARS-CoV-2”) was first identified in late-2019 and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the SARS-CoV-2 pandemic, many companies have experienced disruptions of their operations and the markets they serve. The Company has taken several temporary precautionary measures intended to help ensure the well-being of its employees and contractors and to minimize business disruption. The Company considered the impact of SARS-CoV-2 pandemic on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s results of operations and financial position at September 30, 2022. The full extent of the SARS-CoV-2 pandemic impacts on the Company’s operations and financial condition is uncertain. The Company has experienced slower than normal enrollment and treatment of patients, and a prolonged SARS-CoV-2 pandemic could have a material adverse impact on the Company’s business and financial results, including the timing and ability of the Company to raise capital, initiate and/or complete current and/or future preclinical studies and/or clinical trials, disrupt the Company’s regulatory activities, and/or have other adverse effects on the Company’s clinical development. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2021 filed with the SEC on March 29, 2022. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.

Liquidity and Going Concern

Liquidity and Going Concern	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s cash, cash equivalents, and restricted cash were $ 1,711,351 at September 30, 2022 which includes $ 1,644,321 of restricted cash resulting from a grant received from the State of Tennessee. The Company’s working capital deficiency was $ 6,924,589 and $ 4,258,679 as of September 30, 2022 and December 31, 2021, respectively. The Company continues to incur significant operating losses. Management expects that significant on-going operating expenditures will be necessary to successfully implement the Company’s business plan and develop and market its products. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these unaudited condensed consolidated financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to develop PV-10, PH-10, and/or any other halogenated xanthene-based drug products, and to raise additional capital. The Company plans to access capital resources through possible public or private equity offerings, including the 2022 financing (see Note 5), exchange offers, debt financings, corporate collaborations, or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, although no assurance can be provided that it will continue to be successful in the future. If the Company is unable to raise sufficient capital, it will not be able to pay its obligations as they become due. The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, the Company cannot assure that it will be successful in co-developing, licensing, and/or commercializing PV-10, PH-10, and/or any other halogenated xanthene-based drug candidate developed by the Company or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2022 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, the Company cannot provide assurance that it will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Since the date the Company’s December 31, 2021 consolidated financial statements were issued in its 2021 Annual Report, there have been no material changes to the Company’s significant accounting policies, except as disclosed below. Recently Adopted Accounting Standards In October 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-10 “Codification Improvements” On May 3, 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of September 30, 2022 and December 31, 2021, the Company’s cash equivalents consist of Treasury bills of $ 0 42,594 Restricted Cash Restricted cash consists of a grant award of $ 2,500,000 855,679 Cash Concentrations Cash, cash equivalents, and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $ 250,000 1,461,351 2,856,942 Reclassifications Certain prior year balances have been reclassified in order to conform to current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share. Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares September 30, September 30, 2022 2021 Warrants 487,500 512,500 Options 3,425,000 3,625,000 Convertible preferred stock 105,081,847 104,557,737 2021 unsecured convertible notes 8,602,376 - 2022 unsecured convertible notes 646,952 - Total potentially dilutive shares 118,243,675 108,695,237

Other Accrued Expenses

Other Accrued Expenses	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Other Accrued Expenses	4. Other Accrued Expenses The following table summarizes the other accrued expenses at September 30, 2022 and December 31, 2021: Schedule of Other Accrued Expenses September 30, 2022 December 31, 2021 Accrued payroll and taxes $ 300,691 $ 174,533 Accrued vacation 57,088 42,871 Accrued directors’ fees 1,849,339 1,560,589 Accrued other expenses 237,106 224,493 Total Other Accrued Expenses $ 2,444,224 $ 2,002,486

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Convertible Notes Payable	5. Convertible Notes Payable 2021 Financing Schedule of Convertible Notes Payable Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2022 $ 1,260,000 $ 200,000 $ 1,460,000 Issued 50,000 - 50,000 Balance as of March 31, 2022 1,310,000 200,000 1,510,000 Issued 500,000 - 500,000 Balance as of June 30, 2022 1,810,000 200,000 2,010,000 Beginning Balance 1,810,000 200,000 2,010,000 Issued - 325,000 325,000 Balance as of September 30, 2022 $ 1,810,000 $ 525,000 $ 2,335,000 Ending Balance $ 1,810,000 $ 525,000 $ 2,335,000 On August 16, 2022, the 2021 Note from a related party investor (a Company officer) was extended for up to one additional year to expire on August 16, 2023 For further details on the terms of the 2021 Financing and the details of the 2021 Notes, refer to our Form 10-K as filed with the SEC on March 29, 2022. On September 20, 2022, the Board approved the closure of the 2021 Financing. As of September 30, 2022, the Company had received 2021 Notes proceeds of $ 2,335,000 525,000 2022 Financing Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2022 $ - $ - $ - Issued - - - Balance as of March 31, 2022 - - - Issued - - - Balance as of June 30, 2022 - - - Beginning Balance - - - Issued - 185,000 185,000 Balance as of September 30, 2022 $ - $ 185,000 $ 185,000 Ending Balance $ - $ 185,000 $ 185,000 On September 20, 2022, the Board approved a Financing Term Sheet (the “2022 Term Sheet”), which set forth the terms under which the Company will use its best efforts to arrange for financing of a maximum of $ 5,000,000 185,000 Pursuant to the 2022 Term Sheet, the 2022 Notes (defined below) will convert into shares of the Company’s Series D-1 Preferred Stock twelve months after the issue date of a 2022 Note, subject to certain exceptions. The 2022 Financing will be in the form of an unsecured convertible loans (the “2022 Loan”) from the investors (the “2022 Loan Investors”) and evidenced by convertible promissory notes (individually, a “2022 Note” and collectively, the “2022 Notes”). In addition to customary provisions, the 2022 Notes will contain the following provisions: (i) The 2022 Loan will bear interest at the rate of eight percent ( 8 (ii) In the event there is a change of control of the Board, the term of the 2022 Notes will be accelerated and all amounts due under the 2022 Notes may be immediately due and payable at the 2022 Loan Investors’ option; (iii) The outstanding principal amount and interest payable under the 2022 Loan may be convertible at the 2022 Loan Investors’ option into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $ 2.8620 10 (iv) The outstanding principal amount and interest payable under the 2022 Loan will be automatically convertible into shares of the Company’s Series D-1 Preferred Stock twelve (12) months after the issue date of a 2022 Note. The embedded conversion options associated with the 2022 Note do not require bifurcation and treatment as a derivative liability and they do not represent a beneficial conversion feature because the effective conversion price is not at a discount to the commitment date market price. For further details on the terms of the 2022 Financing and the details of the 2022 Notes, refer to our Form 8-K as filed with the SEC on September 26, 2022.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable The Company obtained short-term financing from AFCO Insurance Premium Finance for our commercial insurance policies. As of September 30, 2022 and December 31, 2021, the balance of the note payable was $ 72,135 238,452

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions During the three months ended September 30, 2022 and 2021, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $ 42,400 21,200 18,750 18,750 During the nine months ended September 30, 2022 and 2021, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $ 127,200 148,400 56,250 56,250 Accrued director fees for Mr. Horowitz as of September 30, 2022 and December 31, 2021 were $ 337,500 281,250 190,800 127,200 See Note 5 for details of other related party transactions. Director fees during the three months ended September 30, 2022 and 2021 were $ 96,250 96,250 288,750 288,750 1,849,339 1,560,589

Stockholders_ Deficit

Stockholders’ Deficit	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders’ Deficit	8. Stockholders’ Deficit Preferred Stock During the nine months ended September 30, 2022, the Company issued 52,411 150,000 Common Stock During the nine months ended September 30, 2022, the Company issued an aggregate of 25,000 1,525 During the nine months ended September 30, 2022, the Company issued an aggregate of 25,000 1,500 Options During the nine months ended September 30, 2022, the Company did not issue any options. The following table summarizes option activity during the nine months ended September 30, 2022: Summary of Option Activity Weighted Average Shares Exercise Price Outstanding and exercisable at January 1, 2022 3,625,000 $ 0.32 Granted - - Exercised - - Forfeited (200,000 ) 0.86 Outstanding and exercisable at September 30, 2022 3,425,000 $ 0.29 The following table summarizes information about options outstanding at September 30, 2022: Summary of Stock Options Outstanding Number Outstanding and Exercisable Weighted Average Intrinsic Value at September 30, Remaining Contractual at September 30, Exercise Price 2022 Life 2022 $ 0.12 2,425,000 3.10 $ - $ 0.29 100,000 3.10 $ - $ 0.67 200,000 0.90 $ - $ 0.75 550,000 3.20 $ - $ 0.88 150,000 1.80 $ - 3,425,000 2.96 $ - Warrants During the nine months ended September 30, 2022, the Company did not issue any warrants. The following table summarizes warrant activity during the nine months ended September 30, 2022: Summary of Warrant Activity Weighted Average Shares Exercise Price Outstanding and exercisable at January 1, 2022 512,500 $ 0.92 Granted - - Exercised - - Forfeited (25,000 ) 0.29 Outstanding and exercisable at September 30, 2022 487,500 $ 0.95 The following table summarizes information about warrants outstanding at September 30, 2022: Summary of Warrants Outstanding Number Outstanding and Exercisable Weighted Average Intrinsic Value Exercise Price 2022 Life 2022 $ 0.29 100,000 0.97 $ - $ 1.00 18,000 1.64 $ - $ 1.12 366,000 1.64 $ - $ 2.00 3,500 1.64 $ - 487,500 1.50 $ - Holders of the outstanding warrants are not entitled to vote and the exercise prices of such warrants are subject to customary anti-dilution provisions. Annual Stockholder Meeting Proposals The Company held its annual meeting of stockholders on June 22, 2022. As proposal number 4, stockholders authorized the Company’s board of directors (the “Board”) to amend the Company’s Certificate of Incorporation, as amended by the Certificate of Designation of Series D Convertible Preferred Stock and Certificate of Designation of Series D-1 Convertible Preferred Stock (the “Certificates of Designation”), to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50 As proposal number 5, the Company’s stockholders also authorized the Board, given the stockholders’ approval of proposal number 4, to amend the Company’s Certificate of Incorporation, as amended by the Certificates of Designation, to decrease the number of authorized shares of the Company’s common stock and preferred stock by the same reverse stock split ratio determined by the Board, consistent with the Board’s recommendation. The Board has not acted on these stockholder authorizations as of the filing date.

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases
Leases	9. Leases The Company leased 4,500 five years 6,100 On June 30, 2022, the lease expired and was not renewed. On June 18, 2022, the Company moved into 2,700 three years 4,053 4,278 Total operating lease expense for the three months ended September 30, 2022 was $ 12,497 8,331 4,166 15,887 10,591 5,296 Total operating lease expense for the nine months ended September 30, 2022 was $ 50,548 33,698 16,850 63,693 42,462 21,231 A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities For The Nine Months Ended September 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 50,784 $ 64,231 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 130,422 $ - Weighted Average Remaining Lease Term Operating leases 2 years 9 months 9 months Weighted Average Discount Rate Operating leases 5 8.0 % 8.0 % Future remaining minimum payments under the Company’s non-cancellable lease obligations as of September 30, 2022 were as follows: Schedule of Future Minimum Payments Under Non-cancellable Lease Years Amount 2022 $ 12,159 2023 49,311 2024 50,663 2025 25,669 Total future minimum lease payments 137,802 Less: amount representing imputed interest (9,406 ) Total $ 128,396

Grants

Grants	9 Months Ended
	Sep. 30, 2022
Grants
Grants	10. Grants On October 25, 2021, the Company received a grant award of $ 2,500,000 from the State of Tennessee for the study of animal cancers and dermatological disorders for the period October 15, 2021 to June 30, 2022 (the “Tennessee Grant” or “Grant”). The Tennessee Grant was pre-funded; therefore, the funds do not need to be used in full by June 30, 2022. The Tennessee Grant was provided as reimbursement of research and development expenses related to the development of animal health drug products. The Company has elected gross presentation of the Tennessee Grant income earned and the related research and development expenses with Grant income presented as Grant revenue in the period in which it is earned, and qualifying costs presented as research and development expenses included in the Company’s income from operations, in the period that such costs are incurred. As of September 30, 2022, $ 1,675,795 has been recorded as unearned Grant revenue liability on the accompanying condensed consolidated balance sheets. The Company recorded $ 824,205 of grant revenue during the nine months ended September 30, 2022.

License Transactions

License Transactions	9 Months Ended
	Sep. 30, 2022
License Transactions
License Transactions	11. License Transactions In the third quarter of 2019, the Company entered into a dialog with Bascom Palmer Eye Institute (“BPEI”) regarding collaboration on BPEI’s ophthalmic photodynamic antimicrobial therapy (“PDAT”) using the Company’s pharmaceutical-grade RBS. On February 16, 2022, and later amended on May 11, 2022, the Company entered into an option agreement with the University of Miami (“UM”) for an exclusive worldwide license of intellectual property (“IP”) developed by the Ophthalmic Biophysics Center (“OBC”) of BPEI that included the use of OBC’s PDAT medical device in combination with formulations of the Company’s pharmaceutical-grade RBS for the treatment of bacterial, fungal, and viral infections of the eye. The Company completed the arrangements of this collaboration during the third quarter of 2022, whereby the Company paid $5,000 for the option that expires on May 31, 2023, and agreed to pay up to $10,000 of new UM patent expenses for this IP during the period of the option and up to $25,000 of past UM patent expenses for this IP. The Company also entered into a sponsored research agreement with UM on September 16, 2022 to study the combination of OBC’s PDAT and TOP PV-305, a formulation of the Company’s pharmaceutical-grade RBS, for the treatment of infectious keratitis. This sponsored research by the Company is not associated with BPEI’s clinical efforts to utilize non-pharmaceutical grade rose bengal.

Commitments, Contingencies and

Commitments, Contingencies and Litigation	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Litigation	12. Commitments, Contingencies and Litigation The Company may, from time to time, be involved in litigation arising from the ordinary course of business and/or that may be expected to be covered by insurance. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events The Company has evaluated events that have occurred after the balance sheet and through the date the condensed consolidated financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below. Convertible Notes Payable Subsequent to September 30, 2022, the Company entered into a 2022 Note with a non-related party investor in the aggregate principal amount of $ 75,000 Subsequent to September 30, 2022, the Company entered into a 2022 Note with a related party investor (a Company Director) in the aggregate principal amount of $ 92,500

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In October 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-10 “Codification Improvements” On May 3, 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of September 30, 2022 and December 31, 2021, the Company’s cash equivalents consist of Treasury bills of $ 0 42,594
Restricted Cash	Restricted Cash Restricted cash consists of a grant award of $ 2,500,000 855,679
Cash Concentrations	Cash Concentrations Cash, cash equivalents, and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $ 250,000 1,461,351 2,856,942
Reclassifications	Reclassifications Certain prior year balances have been reclassified in order to conform to current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share.
Basic and Diluted Loss Per Common Share	Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares September 30, September 30, 2022 2021 Warrants 487,500 512,500 Options 3,425,000 3,625,000 Convertible preferred stock 105,081,847 104,557,737 2021 unsecured convertible notes 8,602,376 - 2022 unsecured convertible notes 646,952 - Total potentially dilutive shares 118,243,675 108,695,237

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares	Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares September 30, September 30, 2022 2021 Warrants 487,500 512,500 Options 3,425,000 3,625,000 Convertible preferred stock 105,081,847 104,557,737 2021 unsecured convertible notes 8,602,376 - 2022 unsecured convertible notes 646,952 - Total potentially dilutive shares 118,243,675 108,695,237

Other Accrued Expenses (Tables)

Other Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Schedule of Other Accrued Expenses	The following table summarizes the other accrued expenses at September 30, 2022 and December 31, 2021: Schedule of Other Accrued Expenses September 30, 2022 December 31, 2021 Accrued payroll and taxes $ 300,691 $ 174,533 Accrued vacation 57,088 42,871 Accrued directors’ fees 1,849,339 1,560,589 Accrued other expenses 237,106 224,493 Total Other Accrued Expenses $ 2,444,224 $ 2,002,486

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Schedule of Convertible Notes Payable Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2022 $ 1,260,000 $ 200,000 $ 1,460,000 Issued 50,000 - 50,000 Balance as of March 31, 2022 1,310,000 200,000 1,510,000 Issued 500,000 - 500,000 Balance as of June 30, 2022 1,810,000 200,000 2,010,000 Beginning Balance 1,810,000 200,000 2,010,000 Issued - 325,000 325,000 Balance as of September 30, 2022 $ 1,810,000 $ 525,000 $ 2,335,000 Ending Balance $ 1,810,000 $ 525,000 $ 2,335,000 Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2022 $ - $ - $ - Issued - - - Balance as of March 31, 2022 - - - Issued - - - Balance as of June 30, 2022 - - - Beginning Balance - - - Issued - 185,000 185,000 Balance as of September 30, 2022 $ - $ 185,000 $ 185,000 Ending Balance $ - $ 185,000 $ 185,000

Stockholders_ Deficit (Tables)

Stockholders’ Deficit (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Summary of Option Activity	The following table summarizes option activity during the nine months ended September 30, 2022: Summary of Option Activity Weighted Average Shares Exercise Price Outstanding and exercisable at January 1, 2022 3,625,000 $ 0.32 Granted - - Exercised - - Forfeited (200,000 ) 0.86 Outstanding and exercisable at September 30, 2022 3,425,000 $ 0.29
Summary of Stock Options Outstanding	The following table summarizes information about options outstanding at September 30, 2022: Summary of Stock Options Outstanding Number Outstanding and Exercisable Weighted Average Intrinsic Value at September 30, Remaining Contractual at September 30, Exercise Price 2022 Life 2022 $ 0.12 2,425,000 3.10 $ - $ 0.29 100,000 3.10 $ - $ 0.67 200,000 0.90 $ - $ 0.75 550,000 3.20 $ - $ 0.88 150,000 1.80 $ - 3,425,000 2.96 $ -
Summary of Warrant Activity	The following table summarizes warrant activity during the nine months ended September 30, 2022: Summary of Warrant Activity Weighted Average Shares Exercise Price Outstanding and exercisable at January 1, 2022 512,500 $ 0.92 Granted - - Exercised - - Forfeited (25,000 ) 0.29 Outstanding and exercisable at September 30, 2022 487,500 $ 0.95
Summary of Warrants Outstanding	The following table summarizes information about warrants outstanding at September 30, 2022: Summary of Warrants Outstanding Number Outstanding and Exercisable Weighted Average Intrinsic Value Exercise Price 2022 Life 2022 $ 0.29 100,000 0.97 $ - $ 1.00 18,000 1.64 $ - $ 1.12 366,000 1.64 $ - $ 2.00 3,500 1.64 $ - 487,500 1.50 $ -

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases
Schedule of Right-of-use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities For The Nine Months Ended September 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 50,784 $ 64,231 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 130,422 $ - Weighted Average Remaining Lease Term Operating leases 2 years 9 months 9 months Weighted Average Discount Rate Operating leases 5 8.0 % 8.0 %
Schedule of Future Minimum Payments Under Non-cancellable Lease	Future remaining minimum payments under the Company’s non-cancellable lease obligations as of September 30, 2022 were as follows: Schedule of Future Minimum Payments Under Non-cancellable Lease Years Amount 2022 $ 12,159 2023 49,311 2024 50,663 2025 25,669 Total future minimum lease payments 137,802 Less: amount representing imputed interest (9,406 ) Total $ 128,396

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$ 1,711,351	$ 3,106,942	$ 254,083	$ 97,231
Restricted Cash	1,644,321
[custom:WorkingCapitalDeficiency-0]	$ 6,924,589	$ 4,258,679

Schedule of Securities Excluded

Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	118,243,675	108,695,237
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	487,500	512,500
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	3,425,000	3,625,000
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	105,081,847	104,557,737
2021 Unsecured Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	8,602,376
2022 Unsecured Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	646,952

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative) - USD ($)	Oct. 25, 2021	Sep. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Cash equivalent - treasury bills		$ 0	$ 42,594
Proceeds from grant	$ 2,500,000
Payment to vendors for expense	$ 855,679
Insured limits		250,000
Cash in excess FDIC insured amount		$ 1,461,351	$ 2,856,942

Schedule of Other Accrued Expen

Schedule of Other Accrued Expenses (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued payroll and taxes	$ 300,691	$ 174,533
Accrued vacation	57,088	42,871
Accrued directors’ fees	1,849,339	1,560,589
Accrued other expenses	237,106	224,493
Total Other Accrued Expenses	$ 2,444,224	$ 2,002,486

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	3 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021
Short-Term Debt [Line Items]
Issued				$ 3,541,222
Convertible Notes Payable [Member] | 2021 Note [Member]
Short-Term Debt [Line Items]
Beginning Balance	$ 2,010,000	$ 1,510,000	$ 1,460,000
Issued	325,000	500,000	50,000
Ending Balance	2,335,000	2,010,000	1,510,000
Convertible Notes Payable [Member] | 2022 Note [Member]
Short-Term Debt [Line Items]
Beginning Balance
Issued	185,000
Ending Balance	185,000
Convertible Notes Payable [Member] | Non-Related Party [Member] | 2021 Note [Member]
Short-Term Debt [Line Items]
Beginning Balance	1,810,000	1,310,000	1,260,000
Issued		500,000	50,000
Ending Balance	1,810,000	1,810,000	1,310,000
Convertible Notes Payable [Member] | Non-Related Party [Member] | 2022 Note [Member]
Short-Term Debt [Line Items]
Beginning Balance
Issued
Ending Balance
Convertible Notes Payable [Member] | Related Party [Member] | 2021 Note [Member]
Short-Term Debt [Line Items]
Beginning Balance	200,000	200,000	200,000
Issued	325,000
Ending Balance	525,000	200,000	200,000
Convertible Notes Payable [Member] | Related Party [Member] | 2022 Note [Member]
Short-Term Debt [Line Items]
Beginning Balance
Issued	185,000
Ending Balance	$ 185,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)		9 Months Ended
	Aug. 16, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 20, 2022
Short-Term Debt [Line Items]
Proceeds from convertible debt		$ 550,000	$ 1,700,000
Proceeds from related party investor		510,000	$ 200,000
2021 Note [Member] | Officer [Member]
Short-Term Debt [Line Items]
Debt instrument maturity date	Aug. 16, 2023
2021 Note [Member] | Company Officer And Company Director [Member]
Short-Term Debt [Line Items]
Proceeds from convertible debt		2,335,000
Proceeds from related party investor		$ 525,000
2022 Note [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate, stated percentage		8%
2022 Note [Member] | 2022 [Member] | Share Based Compensation Award First And Final Tranche [Member]
Short-Term Debt [Line Items]
Financing arrangement amount				$ 5,000,000
2022 Note [Member] | Director [Member]
Short-Term Debt [Line Items]
Due from related party investor		$ 185,000
2022 Note [Member] | Investors [Member] | Series D1 Convertible Preferred Stock [Member]
Short-Term Debt [Line Items]
Preferred stock price per shares		$ 2.8620
Conversion of stock share issued		10

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Note payable	$ 72,135	$ 238,452

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Director fees	$ 96,250	$ 96,250	$ 288,750	$ 288,750
Accrued directors fees	1,849,339		1,849,339		$ 1,560,589
Mr Bruce Horowitz [Member]
Related Party Transaction [Line Items]
Professional fees	42,400	21,200	127,200	148,400
Accrued directors fees	337,500		337,500		281,250
Mr Bruce Horowitz [Member] | Director [Member]
Related Party Transaction [Line Items]
Director fees	$ 18,750	$ 18,750	56,250	$ 56,250
Mr Bruce Horowitz [Member] | Director [Member] | Capital Strategists [Member]
Related Party Transaction [Line Items]
Professional fees			$ 190,800		$ 127,200

Summary of Option Activity (Det

Summary of Option Activity (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Equity [Abstract]
Number of Options Outstanding and exercisable, beginning balance | shares	3,625,000
Weighted Average Exercise Price Outstanding and exercisable, beginning balance | $ / shares	$ 0.32
Number of Options, Granted | shares
Weighted Average Exercise Price, Granted | $ / shares
Stock options, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Stock options, Forfeited | shares	(200,000)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 0.86
Number of Options Outstanding and exercisable, Ending balance | shares	3,425,000
Weighted Average Exercise Price Outstanding and exercisable, Ending balance | $ / shares	$ 0.29

Summary of Stock Options Outsta

Summary of Stock Options Outstanding (Details)	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding	3,425,000
Weighted Average Remaining Contractual Life	2 years 11 months 15 days
Intrinsic value, Beginning Balance | $
Intrinsic value, Ending Balance | $
Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.12
Number Outstanding	2,425,000
Weighted Average Remaining Contractual Life	3 years 1 month 6 days
Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.29
Number Outstanding	100,000
Weighted Average Remaining Contractual Life	3 years 1 month 6 days
Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.67
Number Outstanding	200,000
Weighted Average Remaining Contractual Life	10 months 24 days
Range Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.75
Number Outstanding	550,000
Weighted Average Remaining Contractual Life	3 years 2 months 12 days
Range Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 0.88
Range Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding	150,000
Weighted Average Remaining Contractual Life	1 year 9 months 18 days

Summary of Warrant Activity (De

Summary of Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Equity [Abstract]
Warrants Outstanding and exercisable, beginning balance | shares	512,500
Weighted Average Exercise Price Outstanding and exercisable, beginning balance | $ / shares	$ 0.92
Warrants, Granted | shares
Weighted Average Exercise Price, Granted | $ / shares
Warrants, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Warrants, Forfeited | shares	(25,000)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 0.29
Warrants Outstanding and exercisable, Ending balance | shares	487,500
Weighted Average Exercise Price Outstanding and exercisable, Ending balance | $ / shares	$ 0.95

Summary of Warrants Outstanding

Summary of Warrants Outstanding (Details)	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and exercisable, Ending balance	487,500
Weighted Average Remaining Contractual Life, Warrants Exercisable	1 year 6 months
Share based compensation arrangement by share based payment award non options outstanding intrinsic value | $
Share based compensation arrangement by share based payment award non options outstanding intrinsic value | $
Warrant [Member] | Range One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants outstanding, Exercise price | $ / shares	$ 0.29
Warrants Outstanding and exercisable, Ending balance	100,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	11 months 19 days
Warrant [Member] | Range Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants outstanding, Exercise price | $ / shares	$ 1
Warrants Outstanding and exercisable, Ending balance	18,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	1 year 7 months 20 days
Warrant [Member] | Range Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants outstanding, Exercise price | $ / shares	$ 1.12
Warrants Outstanding and exercisable, Ending balance	366,000
Weighted Average Remaining Contractual Life, Warrants Exercisable	1 year 7 months 20 days
Warrant [Member] | Range Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants outstanding, Exercise price | $ / shares	$ 2
Warrants Outstanding and exercisable, Ending balance	3,500
Weighted Average Remaining Contractual Life, Warrants Exercisable	1 year 7 months 20 days

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Sep. 30, 2021	Sep. 30, 2022
Class of Stock [Line Items]
Issuance of stock, value	$ 150,000
Issuance of stock for service, value
Reverse stock split			to effect a reverse stock split of the Company’s common stock, Series D Convertible Preferred Stock, and Series D-1 Convertible Preferred Stock at a ratio of between 1-for-10 and 1-for-50
Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, value
Issuance of stock for service, value
Common Stock [Member] | Consultant [Member]
Class of Stock [Line Items]
Issuance of stock for service, shares			25,000
Issuance of stock for service, value			$ 1,525
Common Stock [Member] | Employee [Member]
Class of Stock [Line Items]
Issuance of stock for service, shares			25,000
Issuance of stock for service, value			$ 1,500
Series D-1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Issuance of stock, shares			52,411
Issuance of stock, value			$ 150,000

Schedule of Right-of-use Assets

Schedule of Right-of-use Assets and Liabilities (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases	$ 50,784	$ 64,231
Right-of-use assets obtained in exchange for lease obligations: Operating leases	$ 130,422
Weighted Average Remaining Lease Term: Operating leases	2 years 9 months	9 months
Weighted Average Discount Rate: Operating leases		8%
Minimum [Member]
Weighted Average Discount Rate: Operating leases	5%
Maximum [Member]
Weighted Average Discount Rate: Operating leases	8%

Schedule of Future Minimum Paym

Schedule of Future Minimum Payments Under Non-cancellable Lease (Details)	Sep. 30, 2022 USD ($)
Leases
2022	$ 12,159
2023	49,311
2024	50,663
2025	25,669
Total future minimum lease payments	137,802
Less: amount representing imputed interest	(9,406)
Total	$ 128,396

Leases (Details Narrative)

Leases (Details Narrative)		3 Months Ended		6 Months Ended	9 Months Ended
	Jun. 18, 2022 USD ($) ft²	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) ft²	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)
Research and Development Expense [Member]
Operating lease, expense		$ 8,331	$ 10,591		$ 33,698	$ 42,462
General and Administrative Expense [Member]
Operating lease, expense		4,166	5,296		16,850	21,231
Property Subject to Operating Lease [Member]
Operating lease, expense		$ 12,497	$ 15,887		$ 50,548	$ 63,693
Knoxville, Tennessee [Member]
Area of land | ft²	2,700			4,500
Lessee, operating lease, term of contract	3 years			5 years
Rent expenses per month				$ 6,100
Knoxville, Tennessee [Member] | Minimum [Member]
Rent expenses per month	$ 4,053
Knoxville, Tennessee [Member] | Maximum [Member]
Rent expenses per month	$ 4,278

Grants (Details Narrative)

Grants (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Oct. 25, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Grants
[custom:ProceedsFromGrantAwardForStudyOfAnimalCancerAndDermatological]	$ 2,500,000
Deferred revenue current		$ 1,675,795		$ 1,675,795		$ 2,500,000
Revenue		$ 314,890		$ 824,205

License Transactions (Details N

License Transactions (Details Narrative)	9 Months Ended
	Sep. 30, 2022
License Transactions
License transaction description	the Company paid $5,000 for the option that expires on May 31, 2023, and agreed to pay up to $10,000 of new UM patent expenses for this IP during the period of the option and up to $25,000 of past UM patent expenses for this IP. The Company also entered into a sponsored research agreement with UM on September 16, 2022 to study the combination of OBC’s PDAT and TOP PV-305, a formulation of the Company’s pharmaceutical-grade RBS, for the treatment of infectious keratitis. This sponsored research by the Company is not associated with BPEI’s clinical efforts to utilize non-pharmaceutical grade rose bengal.

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - 2022 Note [Member] - Subsequent Event [Member]	1 Months Ended
	Nov. 09, 2022 USD ($)
Non-Related Party [Member]
Subsequent Event [Line Items]
Proceeeds from loan	$ 75,000
Related Party [Member]
Subsequent Event [Line Items]
Proceeeds from loan	$ 92,500